Sanofi-Aventis forms Canadian breast cancer collaboration

Sanofi-Aventis and the Canadian firm YM BioSciences have entered into a collaboration to investigate new breast cancer treatments.

The agreement will focus on investigating the effect of combining tesmilifene and docetaxel for the treatment of women with rapidly progressing metastatic breast cancer.

The aim of the study is to determine whether using tesmilifene with docetaxel has the potential to improve clinical response without increasing toxicity in patients.

Tesmilifene has been shown to improve the effectiveness of commonly used chemotherapies while docetaxel is often used in patients with recurrent or metastatic breast cancer.

The initial study, taking place in Europe and the US, will involve up to 39 women with rapidly progressing metastatic breast cancer.

Patients will be administered docetaxel every 21 days and tesmilifene will be administered by a single infusion at the start of each docetaxel cycle.

© Adfero Ltd